Market access

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo)

A review of market access for type 2 diabetes (DPP4 and combo) treatments shows that under the pharmacy benefit, about 39% of the lives under commercial formularies are covered with utilization management restrictions. Around 21% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Colorectal Cancer

A review of market access for colorectal cancer treatments shows that under the pharmacy benefit, about 53% of the lives under commercial formularies are covered with utilization management restrictions. Around 28% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

MMIT Reality Check on Cystic Fibrosis

A review of market access for cystic fibrosis treatments shows that under the pharmacy benefit, about 65% of the lives under commercial formularies are covered with utilization management restrictions. Around 32% of the lives under Medicare formularies are not covered for at least one of the drugs.

0 Comments

Segmentation in Pharma Forecasting Offers Benefits, Challenges

Forecasting in the pharmaceutical industry is an essential task for companies. While firms have long used Excel-based models to conduct forecasts, those models are outdated and unsuited for the sheer amount of data currently available, maintain industry experts who point out that multiple Web-based options exist. In order to give an accurate picture that’s useful for everyone from executives to sales teams, forecasters should create a model that offers detailed segmentation of the market. Doing this is easier said than done, but strategies exist to help evaluate the different options.